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Photopheresis is a new extracorporeal photochemotherapy in which the patient's blood or
certain blood fraction is exposed to light in the presence of a light-activatable drug. The major
engineering elements involved for better system design and patient treatment, such as system
model, cell separation, irradiation, and energy measurement, are discussed.
INTRODUCTION
The therapeutic as well as the harmful effects of light have been known for a long
time. Also, the use oflight combined with photosensitizers for therapeutic purposes has
been in use for some time. For instance, in skin diseases such as psoriasis and vitiligo,
ultraviolet A irradiation in conjunction with oral intake of 8-methoxypsoralen (8-
MOP) has been an established therapy (psoralen/ultraviolet A treatment, or PUVA)
for many years [1,2,3].
As a further development in this field, a new extracorporeal photochemotherapy
technique (UVAR' System) was first reported by Edelson et al. [4,5] for the treatment
ofcutaneous T-cell lymphoma (CTCL) patients. As discussed by other authors in this
issue, this technique has a potential application in many other diseases. In order to
develop an optimized treatment procedure for different patients and diseases, it is
essential to know the physical parameters and engineering aspects of this new
technique.
In extracorporeal photochemotherapy, three major elements-target cells, photo-
sensitizer, and light-are involved. Ideally, the goal of this therapy is to deliver a
predetermined amount of light energy at a specific wavelength, or a range of
wavelengths, to the selected target blood cells only when these cells contain a
predetermined amount of photoactivatable drug. Since there are significant differ-
ences between photodynamic therapy and broad-band photochemotherapy, this
discussion will be limited to the broad-band extracorporeal photochemotherapy
(photopheresis).
SYSTEM MODELS OF PHOTOPHERESIS
This new extracorporeal photochemotherapy can be achieved by following three
different methods. Obviously, many modified versions ofeach of these methods can be
designed to optimize the overall treatment system undergiven conditions. The methods
are:
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a. Single-batch method
b. Multiple-batch method
c. Continuous single-pass method
Single-Batch Method
In this method, a fraction of the patient's circulating blood is removed from the
patient, exposed to the therapeutic light for a predetermined period, and returned to
the patient. Only one batch of blood, whether collected by one collection cycle or
multiple collection cycles, is exposed to the light. For example, in the UVAR
photopheresis system, normally the buffy coat is collected by six cuts. The irradiated
blood fraction could be whole blood or a fractionated blood component, such as buffy
coat or a specific cell fraction.
When the light source is ultraviolet (UV) light and the target cell is other than red
blood cells (white blood cells or platelets for example), it will be much more effective to
remove the red blood cells from the irradiation circuit to the greatest extent possible
and to minimize the shielding effect of red blood cells. The fraction of treated target
cells to total target cells in the patient's circulating system can be expressed by:
F=- [1]
NT
where NP is the number oftreated cells and NT is the total number oftarget cells in the
patient's circulating blood. The patient's circulating whole blood volume can be
estimated by using 78 ml per kilogram ofbody weight [6]. A more accurate estimation
can be made based on sex, body weight, and height [7].
In UVARe photopheresis, the white blood cell yield in buffy coat is a function of
white blood cell count and hematocrit of patient whole blood. With normal blood cell
counts, the yield is approximately 50 percent of processed whole blood. Normally, 1.5
liters of the patient's whole blood are processed in the UVAR photopheresis system.
Therefore, for example, in the case of a 65 kg patient with normal blood counts,
approximately 15 percent of the patient's white blood cells in the circulation will be
treated by the UVAR photopheresis process.
Multiple-Batch System
When the multiple-batch system is used, a portion of the patient's circulating blood
is removed from the patient, exposed to the light, and returned to the patient. In this
system, the process is repeated multiple times. The number of repetitions is a complex
function of many parameters such as total number of target cells to be treated, blood
cell counts, batch volume, patient's peripheral blood volume, and UVA irradiance.
Since already treated blood cells are returned to the patient before the next batch of
blood is removed, some target cells will be treated repeatedly by this method.
Assuming that the blood in the patient's body is well mixed and also that the diffusion
and exchange rates of target cells between the circulating blood system and other
organs are negligible during this treatment period, the fractions of treated and
untreated target cells become a binomial distribution:
(I _f)n + n (l f)n-I .f+ n(n f _ n-2 . f2 + +fn 2!
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and
f= Np/NT
where n is the number ofbatches treated,NPis the number oftarget cells treated in one
batch, and NT is the total of target cells in the patient's circulating system. The term
(I - f)T represents the fraction of the target cells untreated; n(l - f)'- f the
fraction treated once;f the fraction treated n times, and so on. The fraction of target
cells treated at least once is:
F= I -(I _f)n [2]
Normally, the patient cannot tolerate removal of more than 10 percent of the
circulating blood volume, and usually the total extracorporeal blood volume in a
therapeutic device is much less than that. Therefore, the values ofthe terms withf2 or
a higher power in the above equation are very small.
Continuous Single-Pass Method
In the continuous single-pass method, a portion of the patient's peripheral blood is
continuously circulated through an extracorporeal circuit in which the blood or the
desired fraction ofit is exposed to the light for a predetermined period (residence time)
and returned to the patient, a continuous, on-line, single-pass procedure. The fraction
ofthe target cells treated at least once can be expressed by the following equation:
F = I - exp (- V [3]
where VPB is the patient's circulating peripheral blood volume, QB iS the extracorporeal
blood flow rate, t is the total irradiation period (treatment time), and Cis the efficiency
factor. The value of C is 1.0 ifall target cells passing through the irradiation chamber
receive the same amount of light energy, target value. As in the case of the
multiple-batch method, there will be a distribution of target cells which receives
multiple treatments. Therefore, when the therapy is to deliver a specific amount of
light energy to individual cells and toavoid multiple exposure, the single-batch method
would be the most desirable. If, however, only a small fraction oftotal target cells are
treated, the number of cells receiving multiple treatments will be very small and
insignificant.
CELL SEPARATION
Due to the absorptivity of red blood cells, especially to UV light, it is desirable to
reduce the red blood cell concentration of the blood in the irradiation circuit to
minimize the red blood cell shielding effect. For instance, in the UVAR photopheresis
system, the target cells are white blood cells, especially lymphocytes, and the light
source is a broad-band UVA light (320
- 400 nm). The process consists ofthree major
steps: (I) the patient's blood is drawn two hours after oral intake of the photoactivat-
able drug (8-MOP), and buffy coat is collected by centrifugal technique; (2) the
collected buffy coat is diluted in saline and the patient's plasma, irradiated by
ultraviolet A light (UVA light) in an irradiation chamber for a predetermined period;
and, finally, (3) the irradiated buffy coat is returned to the patient. One ofthe key steps
in this system is to reduce the red blood cell contamination in thecollected buffy coat as
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TABLE 1
Average Physical Characteristics of Normal Adult Human Blood Cells [6,8]
Density Diameter
Component (g/cm3) (Am)
Red blood cell 1.093 -8
White blood cell 1.066 7-20
Platelet 1.053 -2
much as possible while keeping the maximum number of target cells in the collected
buffy coat.
During the last 20 years, many different approaches, using a centrifuge, membrane,
or adsorption technique, were attempted by many investigators to separate specific
blood cells from whole blood without damaging or losing their biological activities.
Today, the most reliable and probably the only effective technique is still based on
centrifugal force.
If whole blood in a test tube is allowed to stand overnight and earth's gravity is
permitted to act on individual blood components, the blood will separate into three
distinctive layers: a packed red blood cell layer at the bottom, a thin buffy coat layer in
the middle, and an amber plasma layer on the top. The sedimentation rate of blood
cells in a given gravitational field varies, depending on density, size, shape, and other
physical properties ofblood cells. Table 1 shows the average physical characteristics of
normal adult human blood cells.
Red blood cells not only have higher density but also tend to adhere to each other
and form much larger particles, or rouleaux, in a low shear rate region (<50 sec')
such as stagnant or slowly moving blood.
In a gravitational field such as that inside a centrifuge bowl, the red blood cells, in
rouleaux form, settle tothe bottom ofthedevice. Behind the settling red blood cells, the
white blood cells and platelets settle on top of the red blood cell layer and form the
buffy coat. This sequence is due to the slower sedimentation rates ofwhite blood cells
and platelets because oftheir lower densities and smaller sizes in comparison to the red
blood cell rouleaux. Centrifugation speeds up this separation process by means of
increased gravitational force. The settling red blood cells (rouleaux) replace plasma
and other cells; however, increased cell concentration near the bottom of the device
results in increased cell-cell interaction, which causes trapping of many white cells
inside the packed red blood cell layer. Also, too high a centrifugal force will result in
very rapid settling of all cellular elements, and the small difference in sedimentation
rates between red and white blood cells becomes insignificant. When this effect
happens, even though the process time is shortened, a poor cell separation will occur.
Therefore, the optimal cell separation process requires a delicate adjustment ofprocess
variables, including total process time. This optimum condition will vary, depending on
the type of cell to be collected and the composition of whole blood, especially
hematocrit [8].
It is known that the lymphocyte cells within the buffy coat layer are more
concentrated in the plasma side, while neutrophils and monocytes are higher in
concentration near the red blood cell layer or inside it [9]. In UVAR8 photopheresis,
the buffy coat collection process was designed so that lymphocyte collection could be
maximized while minimizing red blood cell contamination.
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UV IRRADIATION
UVEnergy Delivered
In extracorporeal photochemotherapy, the whole blood or the portion which contains
target blood cells and photoactivatable drug is circulated through an irradiation
chamber. In the UVARs photopheresis system, the buffy coat solution diluted by
plasma and saline is recirculated through a thin fluid path in the PHOTOCEPTOR'
irradiation chamber, a molded UVA-transparent acrylic device.
Normally, in photobiological science the light energy delivered to the sample is
measured by the amount ofenergy delivered per unit surface area, J/cm2, because the
same surface area is exposed to the light for a specified period. In a case such as
UVARD photopheresis, however, the fluid is not transparent to the UV light due
mostly to red blood cell shielding, and only the surface ofthe fluid film is exposed to the
irradiation. Since the fluid surface is continuously renewed during the flow, individual
target cells in the fluid are exposed to the irradiation for only a fraction of the total
exposure period. The light intensity (irradiance) at the surface of the target cell
membrane will be a function of the hematocrit, the plasma absorptivity, and the
distance the light beam has to penetrate. In the PHOTOCEPTOR® irradiation
chamber, the buffy coat film is about 1.4 mm thick, and hematocrit is about 4 to 6
percent on the average. Under these conditions, the blood film is totally opaque to the
UVA light, mostly because ofthe red blood cell shielding. The amount ofUVA energy,
E, delivered to the circulating buffy coat solution can be best expressed by the amount
delivered to the unit volume rather than to the unit surface area:
E Io.A .t
VB
where E = Total UVA energy delivered to the unit volume, J/ml
Io = The average intensity ofUV light (irradiance) at the blood film surface,
w/cm2
A = Total surface area ofthe blood film exposed to the light, in cm2
t = Total irradiation period, in seconds
VB = Total volume recirculated through the irradiation system, in ml




where QB = Blood flow rate through the irradiation chamber, in ml/second.
The fluid channel in the irradiation chamber has to be designed in such a way that
any cell settlement or fluid stagnation should be avoided. In the recirculation system,
the light energy delivered to the target cells is independent of the recirculation flow
rate, while in the single-pass system it is inversely proportional to the flow rate.
Red Blood Cell Shielding
In extracorporeal photochemotherapy, the shielding effect by red blood cells is one
of the major problems. As a sample experiment, human blood buffy coat solutions
'Registered Trademark ofJohnson & Johnson
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FIG. 1. The effect of hematocrit on the viability of UVA-irradiated
human leukocytes (mostly lymphocytes). White blood cells separated by
Ficall/Hypaque technique were suspended in 20 ml of plasma, containing
75 ng/ml of 8-methoxypsoralen in a petri dish. The hematocrit of the
sample solutions was adjusted by adding packed red blood cells. The sample
solutions were stirred by magnetic stirrer and exposed to UVA light
(irradiance, 12 mw/cm2). The UVA energies required to reduce the cell
viability to 20 percent or less after four days were measured and plotted
against percentage of hematocrit.
containing 75 ng/ml of 8-MOP and several different concentrations of red blood cells
were exposed to UVA light. The amount of UVA energy required to reduce the white
blood cell (mostly lymphocyte) viability after four days to below 20 percent was
measured. Figure 1 shows the UVA energy required versus the hematocrit. At zero
hematocrit, only 6 J/ml of UVA energy were needed to achieve the goal. As the
hematocrit increases, however, the required amount of energy increases almost
exponentially. UVA energy is also absorbed by plasma and other blood constituents,
but its magnitude is negligible in comparison to the red blood cell effect. Figure 1
implies that the UVA energy absorption by the red blood cell solution closely follows
Beer's law. The UVA intensity reaching an individual white blood cell's surface
decreases as an exponential function of red blood cell concentration, hematocrit. For
instance, at a hematocrit of 8 percent or more, an extremely small fraction of total
UVA energy delivered will reach white blood cells; the time required is too long to
achieve a desirable photochemical reaction, and the process becomes impractical.
Therefore, it is essential to minimize the red blood cell shielding effect by reducing red
blood cell concentration. If, however, it takes too long to reduce the red blood cell
concentration to the minimum level, it would not be much help in reducing the overall
patient treatment period. Therefore, it is necessary to optimize the overall system by
balancing the cell separation and irradiation periods.
Light Source and Measurement
The best choice of a light source for photochemotherapy is obviously the one with a
maximum output at the wavelength at which the desirable photochemical activity is
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maximum. Therefore, it is extremely helpful to generate an action spectrum for a given
photosensitizer as a function of wavelength and evaluate the shape of the curve. For
instance, photosensitized 8-MOP showed the maximum activity in inhibiting new
DNA synthesis in human lymphocytes at 346 nm, and its action spectrum is fairly
broad [10]. In this situation, the most efficient light source is a broad-band fluorescent
light source with a maximum output at around 346 nm. The fluorescent light bulb in
the UVARs system has its maximum peak at around 350 nm, close to the optimum
wavelength of 346 nm. If the action spectrum shows an extremely sharp peak at a
certain wavelength, an arc lamp with maximum output at that wavelength, or a laser
beam, would be a better choice.
The light intensities from most light sources, including fluorescent bulbs and arc
lamps, decay over time. So, in photochemotherapeutic instruments it is necessary to set
a limit on the life of the light bulb. Otherwise, the intensity must be monitored before
every treatment and the treatment process adjusted accordingly. In the case of
ultraviolet light (UV) irradiance measurement, an accurate monitoring requires
extremely careful planning. It is not unusual to have completely different UVA
irradiance readings by two calibrated UVA detectors from two different manufactur-
ers. For instance, a given UVA detector has its specific response curve as a function of
wavelength. Ideally, it should be a constant value, independent of wavelength, within
the UVA range (320 - 400 nm) and zero at other wavelengths. There is, however, no
such ideal detector, and all detectors have their own characteristic response curves.
Therefore, the best choice ofUVA detector is the one which has a broad response curve
with a maximum response at the wavelength at which the light source produces the
maximum UVA output.
Also, in order to avoid inaccurate readings caused by solarization and instrument
drift, periodic calibration ofthe monitor is necessary. Considering all these potentially
inaccurate measurements oflight energy and, therefore, inadequate patient treatment,
it would be much safer in many instances to put a limit on the light bulb life.
Drug Delivery
As far as the delivery of photoactivatable drug to the target cells is concerned, an
on-line drug addition to the extracorporeal blood circuit would be the most efficient
approach. In the currently available UVAR® photopheresis system, the drug (8-MOP)
is delivered to the target blood cells through oral intake. This route is very inefficient,
and it is extremely difficult to adjust the drug concentration in the target cells
accurately due to individual variation in bioavailability. On-line drug delivery would
not only be precise, but it would also leave a much smaller amount of residual drug in
the patient's body after the treatment.
In conclusion, the development ofan optimized process for extracorporeal photoche-
motherapy requires understanding of each engineering element discussed here and
adjustment of these elements for overall optimum therapy.
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